US 11,234,968 B2 · Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug

Abstract

The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.

Claims12

Dependent claims

A pharmaceutical composition or a kit, comprising:

at least one Valosin containing protein (VCP) inhibitor;
and at least one oncolytic virus, wherein the oncolytic virus is Alphavirus M1 (M1 virus) and the Valosin containing protein (VCP) inhibitor is selected from the group consisting of Eeyarestatin I, NMS-873, CB-5083, RNA interference fragment of VCP (siRNA) and a combination thereof.

Dependencies are inferred from the claim text.

Facts

Application

16/325,960Filed 18 Aug 2017

Priority

CN 201610688100.718 Aug 2016

Published

US 2019/0167641 A16 Jun 2019

Granted

1 Feb 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 31/4178
1,3-Diazoles: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 9/48
Medicinal preparations characterised by special physical form: preparations in capsules, e.g. of gelatin, of chocolate

Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug

Life of this patent

Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug

Life of this patent

Abstract

Claims12